COVID-19 and transtympanic injections for sudden sensorineural hearing loss

ElsevierVolume 44, Issue 2, March–April 2023, 103718American Journal of OtolaryngologyAuthor links open overlay panelAbstractBackground

Multiple reports have linked COVID-19 infection with sudden sensorineural hearing loss (SSNHL), although other studies have failed to demonstrate this association. The current study was conceived to examine the rates of SSNHL across a large, principally national, population by characterizing the rate of transtympanic injections for SSNHL during the pandemic.

Methods

Retrospective review of all patients that underwent transtympanic injection from 2019 to 2020.

Results

Covering a unique beneficiary population of 9.6 million individuals of all ages in the United States, a statistically significant decrease in transtympanic injections for SSNHL was performed from 2019 to 2020 (p = 0.04, IRR = 0.91, 95 % CI = 0.84–0.99). No patient receiving a transtympanic injection also had a COVID-19 diagnosis.

Conclusions

These findings support the idea that COVID-19 infections do not clinically significantly increase patients' risk of developing SSNHL. In fact, the decreased exposure through social isolation to other common viruses implicated in causing SSNHL may have actually led to a lower rate of SSNHL during the pandemic.

Keywords

COVID

Sudden sensorineural hearing loss

Population-based

United States

AbbreviationsSSNHL

Sudden Sensorineural Hearing Loss

CPT

Current Procedural Terminology

ICD10

International Classification of Disease, Tenth Revision

View Abstract

Published by Elsevier Inc.

留言 (0)

沒有登入
gif